NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Confirmed

**Date and time:** Tuesday 11 January 2022

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien (Chair topic 1) Present for all items
2. Dr Lindsay Smith (Chair topic 2) Items 5 to 5.2.2
3. Dr Alex Cale Items 1 to 4.2.2
4. Michael Chambers Present for all items
5. Dr Prithwiraj Das Items 1 to 4.2.2
6. Dr David Foreman Present for all items
7. Dr Rob Forsyth Present for all items
8. Dr Natalie Hallas Present for all items
9. John Hampson Present for all items
10. Dr Nigel Langford Present for all items
11. Dr Andrea Manca Present for all items
12. Iain McGowan Present for all items
13. Dr Mudasar Mushtaq Present for all items
14. Dr Richard Nicholas Present for all items
15. Ugochi Nwulu Present for all items
16. Stella O’Brien Present for all items
17. Professor Subhash Pokhrel Present for all items
18. Professor Andrew Renehan Present for all items
19. Professor Matthew Stevenson Present for all items
20. Professor Paul Tappenden Present for all items
21. Dr Derek Ward Present for all items

NICE staff present

Ross Dent, Associate Director Items 1 to 4.2.2

Jasdeep Hayre, Associate Director Items 5 to 5.2.2

Louise Jafferally, Project Manager Items 1 to 5.1.3

Gavin Kenny, Project Manager Items 5 to 5.2.2

Alexandra Filby, Health Technology Assessment Adviser Items 1 to 4.2.2

Sally Doss, Health Technology Assessment Adviser Items 5 to 5.2.2

Catherine Parker, Health Technology Assessment Analyst Items 1 to 4.2.2

Nigel Gumbleton, Health Technology Assessment Analyst Items 5 to 5.2.2

Benjamin Gregory, Business Analyst, RIA Items 1 to 4.2.2 & 5.1.3 to 5.2.2

Ruth Melville, Senior Medical Editor Items 1 to 4.2.2

Benjamin Pearce, Senior Medical Editor Items 5 to 5.2.2

Ella Livingstone, Technical Analyst, Commercial Risk Assessment, Present for all items

Emily Eaton Turner, Technical Analyst, Commercial Risk Assessment, Present for all items

Neha Jiandani, Technical Analyst, Commercial Risk Assessment Items 1 to 4.2.2

Mandy Tonkinson, Public Involvement Adviser, PIP Items 1 to 4.1.3 & 5 to 5.1.3

Lucinda Evans, Coordinator, Corporate Office Items 1 to 4.2.2

Gemma Smith, Coordinator, COT Present for all items

Iain Cannell, Administrator, TA Items 1 to 4.2.2

Ismahan Abdullah, Administrator, TA Items 5 to 5.2.2

External assessment group representatives present

Nigel Armstrong, Kleijnen Systematic Reviews Ltd Items 1 to 4.1.3

Sabine Grimm, Kleijnen Systematic Reviews Ltd Items 1 to 4.1.3

James Mahon, Liverpool Reviews, and implementation Group Items 5 to 5.1.3

Sophie Beale, Liverpool Reviews, and implementation Group Items 5 to 5.1.3

Clinical, Patient & NHS England experts present

Professor Riyaz Patel, Professor of Cardiology and Consultant Cardiologist, clinical expert nominated by Cochrane Heart Group, Items 1 to 4.1.3

Dr Peter Winocour, Consultant Diabetologist and Endocrinologist, Clinical expert nominated by Association of British Clinical Diabetologists, Items 1 to 4.1.3

Jules Payne, Patient expert nominated by HEART UK, Items 1 to 4.1.3

Professor Gary McVeigh, Clinical Adviser, NHS England, Items 1 to 4.1.3

Christopher Curtis, Patient expert nominated by The Swallows Head & Neck Cancer Charity, Items 5 to 5.1.3

Professor Peter Clark, Cancer Drug Fund Clinical Lead, NHS England, Items 5 to 5.2.2

Dr Ramkumar Shanmugasundaram, Consultant Clinical Oncologist, clinical expert nominated by The Royal College of Radiologists, Items 5 to 5.1.3

Dr Robert Mefcalf, Consultant Medical Oncology, Clinical expert nominated by NCRI-ACP-RCP, Items 5 to 5.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Professor Stephen O’Brien welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted committee member apologies.

### News and announcements

* 1. None

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 14 December 2021.

### Appraisal of Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides [ID3831]

* 1. Part 1 – Open session
		1. The chair Professor Stephen O’Brien welcomed the invited clinical and patient experts, external assessment group representatives, members of the public and company representatives from Amarin Pharma
		2. The chair asked all committee members, clinical and patient experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Nominated clinical expert Professor Riyaz Patel declared the following interests.
* He has received honoraria and education grants from other companies not related to this product but involved with lipid management, including Amgen, Sanofi, Novartis, and Bayer.
* He has a small private practice dealing with patients with general cardiology issues.
* Leads a strategic effort in CVD prevention locally in East London and chair the NL ODN group to enhance CVD prevention in primary care.
* Is a committee member for Pan London groups on CVD prevention and familial hypercholesterolaemia.
* His institution (Barts Health) has joint working agreements with industry. But not with the manufacturer of this agent.
* He has recently been appointed topic advisor for the upcoming NICE update on CVD prevention and Lipids.
* His private practice includes general cardiology and lipid disorders.
* He is the clinical lead for CVD prevention at Barts Health and oversee the lipid service. It was agreed that his declarations would not prevent Professor Patel from providing expert advice to committee.
* Nominated clinical expert Dr Peter Wintour declared financial interests as he has received honoraria for delivering educational meetings and/or attending advisory boards for Abbott, Astra Zeneca, Bayer, BI, Eli Lilly, MSD, Napp, Sanofi, Novo and Vifor Pharmaceuticals. It was agreed that his declarations would not prevent Dr Wintour from providing expert advice to committee.
* Nominated patient expert Jules Payne declared an indirect financial interest as HEART UK has received funding from Bayer, Novartis, Daiichi Sankyo, Boehringer Ingelheim, Sanofi and Amgen.
* No further conflicts of interest were declared for this appraisal.
	+ 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Rob Forsyth, Stella O’Brien, and Professor Subhash Pokhrel.
	1. Part 2 – Closed session (company representatives, clinical & patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10736>.

### Appraisal of pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma [ID3972]

* 1. Part 1 – Open session
		1. The chair Dr Lindsay Smith welcomed the invited clinical and patient experts, the National Clinical lead for Cancer drugs fund, external assessment group representatives, and company representatives from MSD.
		2. The chair asked all committee members, clinical and patient experts, National Clinical lead for Cancer drugs fund, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Dr Mudasar Mushtaq declared non-financial professional interests as he works in head and neck cancer with the attending clinical expert Dr Robert Metcalf, Dr Mushtaq confirmed he has no financial or academic interests. It was agreed his declaration would not prevent Dr Mushtaq from attending discussions on this appraisal.
* Nominated clinical expert Dr Robert Metcalf declared financial interest as received an honorarium from MSD to chair a national Head and Neck meeting on the use of pembrolizumab in the NHS in the context of the new NICE guidance, Dr Metcalf confirmed he has no ongoing financial relationship with MSD. it was agreed that his declaration would not prevent Dr Metcalf from providing expert advice to committee.
* No further conflicts of interest were declared for this appraisal.
	+ 1. The Chair led a discussion of the consultation comments presented to the committee.
	1. Part 2 – Closed session (company representatives, clinical and patient experts and external assessment group representatives were asked to leave the meeting).
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/ta661>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Tuesday 8 March 2022 and will start promptly at 09.30.